© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Finch Therapeutics Group, Inc. (FNCH) shows an Average True Range (ATR) of 0.35 and an Enterprise Value of 8.7M. Its average trading volume over the past 3 months is 3.68K, indicating liquidity. These fundamental metrics provide insight into FNCH's underlying financial health and market activity.
Finch Therapeutics Group, Inc. (FNCH) technical indicators as of December 23, 2025: the SMA 20 is -49.83%, SMA 50 at -56.73%, and SMA 200 at -72.98%. The RSI 14 value is 29.56, suggesting its current momentum. These technical analysis signals help assess FNCH's price trends and potential future movements.
Finch Therapeutics Group, Inc. (FNCH) stock performance overview as of December 23, 2025: The 52-week high is $16.1 (currently -94.21% below), and the 52-week low is $10.15 (currently 21.25% above). Over the past year, FNCH's performance is -85.8%, compared to the S&P 500's 12.87% change.
According to market data, Finch Therapeutics Group, Inc. (FNCH) stock's recent performance metrics show that over the last month, FNCH is -47.84%, with a Year-to-Date (YTD) performance of -66.48%. Over the past year, the stock has seen a -85.8% change. These figures summarize FNCH's price movements across various periods, reflecting its historical returns.
According to current financial data, FNCH stock's P/E (TTM) ratio is -1.54, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for FNCH, including P/S (N/A), P/B (2.35), and P/FCF (-0.68), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.